Human Complement C4 AssayMax ELISA Kit (Positive and Low Controls Included)

Name: Human Complement C4 AssayMax ELISA Kit (Positive and Low Controls Included)
Brand: AssayMax&trade; ELISA Kits
SKU: EC2102-8
Availability: InStock

$500.00

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.
Product Size:96 Well Plate

Catalog Number. EC2102-8 Categories: Competitive ELISA, ELISA Kits, Kits Tags: C4, CIV, Complement C4, Complement Component 4, Complement Component IV Brand: AssayMax™ ELISA Kits

Additional information

Format	Competitive ELISA
Entrez Gene	720, 721
Components	Biotinylated Human Complement C4 Protein, Chromogen Substrate (1x), Human Complement C4 Microplate, Human Complement C4 Standard, Low Control, MIX Diluent Concentrate (10x), Positive Control, Sealing Tapes, SP Conjugate (100x), Stop Solution (1x), Wash Buffer Concentrate (20x)
TIme	2 hours
Sensitivity	0.53 µg/ml
Range	0.313 – 5 ug/ml
Samples Type	Plasma, Serum
Associated Disease	Autoimmune Disease, Lupus (SLE)
Species	Human
UniProt	P0C0L4, P0C0L5
Storage	Refer to component labels for details
Plex	1
Usage	For Research Use Only, Not To Be Used For Diagnostic Purposes

Documentation

Publications

"* Ozawa Y et al. (2021) Changes in serum complements and their regulators in generalized myasthenia gravis. Euro. J. Neuro. 28:314-322.
"* Andersone BJ (2020) Lymphatic Filariasis: Host and parasite factors and the pathogenesis of systemic adverse events following treatment. Washington University in St. Louis Electronic Theses and Dissertations. 2160.
"* Chaika K et al. (2019) The status of the C3 fnd C4 fractions of the complement system in children with Henoch-Schelan purpura. Pediatr Pol. 94 (4): 229-234.
"* Andersen BJ et al. (2019) Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. PLoS Negl Trop Dis. 13(9):e0007697.
"* Okuzaki D et al. (2017) FCN1 (M-fcolin), which directly associates with immunoglobulin G1, is a molecular target of intravenous immunoglobulin therapy for Kawasaki disease. Sci Rep. 7(1):11334.
"* Hoefman S et al. (2018) Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies. United States Patent 10118967
"* Yurova BA et al. (2017) Changes in the complement system in membranoproliferative glomerulonephritis. https://doi.org/10.17116/terarkh201789669-77.
"* Wasiak S et al. (2017) Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208). J. of Cardiovasc. Trans. Res. 10:337-347.
"* Mizuno M et al. (2017) High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients. PLoS One. 12(1):e0169111
"* Yadav AP et al. (2015) Activation of Complement System during Ship Voyage and Winter-over Expedition in Antarctica. J Marine Sci Res Dev. 5:3.
"* Sei Y et al. (2015) Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy. Mol Immunol. 65(2):302-9
"* Menzhinskaya IV et al. (2015) Incidence of Autoantibodies to C1Q Complement Component in Women with Miscarriages and Autoantibodies to Phospholipids and Chorionic Gonadotropin. Bull Exp Biol Med. 160(2):260-3.
"* Hoefman S et al. (2015) Treatment of il-6r related diseases. Patent application: US20190119392A1.
"* Ajona D et al. (2015) Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. PLoS One. 10(3):e0119878.
"* Sudzius G et al. (2014) Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjogren's syndrome? Rheumatol Int. 34(2):235-41.
"* Gawad ERA (2014) Role of Anti-nucleosome Antibodies in the Diagnosis of Systemic Lupus Erythematosus and as A Marker for Lupus Nephropathy. THE EGYPTIAN JOURNAL OF IMMUNOLOGY 21(1):57-65
"* EI-Gendy NA et al. (2014) Diagnosis of spontaneous bacterial peritonitis. The Egyptian Journal of Internal Medicine 26(2):53-59
"* Dowling P et al. (2014) Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014 Oct 17;15:904. doi: 10.1186/1471-2164-15-904
"* Koehler EM (2013) Non-alcoholic fatty liver disease. From patient to population. Erasmus University Medical Center Rotterdam. Dissertation.
"* Guichelaar MMJ et al. (2013) Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity 21(9):1935-1941
"* Koehler E et al. (2012) Growth hormone, dehydroepiandrosterone and adiponectin levels in non?alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 32(2):279-86
"* Charlton MR (2012) Serum Biomarkers For Early Detection Of Acute Cellular Rejection. Patent application number: 20120014949 A1
"* Massoud O et al. (2011) Noninvasive Diagnosis of Acute Cellular Rejection in Liver Transplant Recipients: A Proteomic Signature Validated by Enzyme-Linked Immunosorbent Assay. Liver Transpl. 17(6):723-32.
"* Alam HB and Li Y (2011) Biomarkers of hemorrhagic shock. Patent application number: 20130149713

Human Complement C4 AssayMax ELISA Kit (Positive and Low Controls Included)

Additional information

Documentation

Publications

Related products

Human Complement C4 AssayMax ELISA Kit Positive Reference Plasma Control

Human Complement C4 Monoclonal Antibody

Human Complement C4 AssayLite Fluorescent Immunoassay Kit

Human Complement C4 AssayMax ELISA Kit Positive Reference Plasma Control